SARCOMA

FDA approval has been granted to nab-sirolimus for intravenous use as treatment of patients with advanced malignant perivascular epithelioid cell tumors.

A California-based study of devimistat plus hydroxychloroquine for soft tissue sarcoma has enrolled its first patient.

A phase 1b/2 study has shown an 80% clinical activity rate with liposomal annamycin as treatment of soft tissue sarcoma lung metastases.

Following its success in acute myeloid leukemia and other cancers, devimistat is being explored as a treatment option for clear cell sarcoma in a phase 1/2 trial.

Phase 2 data show that tyrosine kinase inhibitors can be combined with chemotherapy to improve outcomes in patients with relapsed or refractory osteosarcoma.

The first patient has been dosed in a trial of FHD-609, a selective protein degrader of bromodomain-containing protein 9, for the treatment of synovial sarcoma.

An orphan drug designation has been granted to the CD40 agonistic monoclonal antibody, sotigalimab, for the treatment of patients with soft tissue sarcoma.

During the 2021 American Society of Clinical Oncology Annual Meeting, multiple trials for targeted treatments were presented for soft tissue sarcoma. Dean Frohlich, PhD, and Brian A. Van Tine, MD, PhD, discuss the the results of some of these presentations, including the Spearhead 1 trial.

The FDA has granted priority review to the New Drug Application for nab-sirolimus for consideration as a treatment for patients with advanced malignant perivascular epithelioid cell tumors.

A phase 3 study has been initiated in order to evaluate the efficacy of the oral MDM2 inhibitor milademetan for the treatment of de-differentiated liposarcoma.

The target number of patients with soft tissue sarcoma lung metastases have been enrolled in the phase 1b/2 study of Annamycin, commencing the recruiting portion of the trial.

New data from the phase 2 SPEARHEAD-1 trial showed that afami-cel can elicit encouraging responses in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.

Progression-free survival and disease control in patients with advanced synovial sarcoma was improved by catequentinib.

Experts discuss advances in gastrointestinal stromal tumors (GIST) and dive into the evolving landscape and ongoing unmet needs.

The FDA has granted fast track designation to Annamycin for the treatment of soft tissue sarcoma lung metastases, according to a press release from Moleculin Biotech, Inc.

In an interview with Targeted Oncology, Margaret von Mehren, MD, reviews the recent advancements in the GIST treatment landscape. She also explains what’s needed to move the needle further in the future.

The novel combined immunotherapy CRX100 has been dosed in the first patient with refractory solid tumors in a phase 1, open-label, dose-escalation study.

Adjuvant imatinib has demonstrated significant improvement in relapse-free survival over a 2-year period and a mild trend toward long-term improvement in failure-free survival as treatment of patients with high-risk gastrointestinal stromal tumors, according to 9.1-year follow-up results from a randomized phase 3 study.

Men appear to be more likely than women to have invasive gastrointestinal stromal tumors originating in the stomach and small intestines. For treatment, an expert says that combined surgery and systemic therapy demonstrates the best outcomes.

In early 2020, the treatment paradigm of soft tissue sarcoma had 3 notable advancements with the FDA approving therapies in epithelioid sarcoma, Kaposi sarcoma, and gastrointestinal stromal tumors.

An Orphan Drug Designation was granted by the FDA to ilixadencel as use for the treatment of patients with soft tissue sarcoma.

The FDA has granted an Orphan Drug Designation to annamycin for the treatment of patients with soft tissue sarcomas.

In an interview with Targeted Oncology, Michael J. Wagner, MD, discussed findings from a single-center experience in Seattle managing patients with sarcoma during the COVID-19 pandemic.

The investigational engineered SPEAR T-cell agent, ADP-A2M4, induced durable responses in patients with synovial sarcoma, according to updated results from the phase 1 clinical trial presented during the Connective Tissue Oncology Society Annual Meeting.

Treatment with the investigation agent INBRX-109 induced responses and decreased the tumor burden in a cohort of patients with chondrosarcoma, according to interim efficacy and safety findings a phase 1 trial in patients with chondrosarcoma, Inhibrx, Inc announced in a press release.

Selinexor induced a statistically significant reduction in the risk of disease progression or death compared with placebo as treatment of patients with advanced unresectable dedifferentiated liposarcoma.

The FDA has granted an Orphan Drug designation to CPI-613 for the treatment of soft tissue sarcoma.

Preliminary activity was observed in an unselected group of patients with miscellaneous soft tissue sarcoma treated with trabectedin in combination with durvalumab in the phase 1b TRAMUNE trial. The results presented during the 2020 European Society of Medical Oncology Virtual Congress demonstrate the feasibility of utilizing this combination in soft tissue sarcoma.

Prolonged progression-free survival was observed with pembrolizumab monotherapy in patients with selected rare sarcoma subtypes treated in the phase 2 AcSé basket study, according to a presentation during the 2020 European Society of Medical Oncology Virtual Congress.

As compared with placebo, regorafenib induced favorable progression-free survival rates at 24 weeks versus placebo in patients with Ewing sarcoma in the phase 2 REGOBONE study. Despite this, the trial failed to meet its primary end point of non-progression at 8 weeks, according to findings presented at the European Society of Medical Oncology Virtual Congress 2020.